http://www.dynavax.com/hepatitis_bt.html
The study evaluated three doses of the candidate therapeutic vaccine escalation in 14 patients with chronic hepatitis B infection, including six patients that were HBeAg negative and eight patients who were HBeAg positive, and found:
The therapeutic regimen was safe and generally well tolerated at all dose levels;
Most common systemic reactions were fatigue and malaise. No SAEs were recorded;
DV601 was found to elicit immune responses at all dose levels, and anti-HBe antibodies were elicited in two of eight (2/8) patients;
Anti-HBs antibodies were elicited in four of 14 (4/14) patients;
Amongst the eight HBeAg positive patients, two had HBeAg clearance, and one of those individuals also had HBsAg clearance;
Three patients are still in the follow-up observation period.
希望赶紧出来
值得关注！